Exendin-4 attenuates cardiac hypertrophy via AMPK/mTOR signaling pathway activation

Biochemical and Biophysical Research Communications

Volumn 468, Issue 1-2, 2015, Pages 394-399

  Zhou, Yue ^a,c   He, Xin ^b,c   Chen, Yili ^a,c   Huang, Yiyi ^a,c   Wu, Lingling ^a,c   He, Jiangui ^a,c  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c BEIJING HOSPITAL   (China)

Author keywords

AMPK; Cardiac hypertrophy; Exendin 4; GLP 1

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MYOSIN HEAVY CHAIN BETA; PHENYLEPHRINE; RNA; ANTIDIABETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PEPTIDE; RAPAMYCIN; S6 KINASE; TARGET OF RAPAMYCIN KINASE; VENOM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SURFACE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; ENZYME ACTIVATION; EXPERIMENTAL CARDIAC HYPERTROPHY; HEART VENTRICLE HYPERTROPHY; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; CARDIOMEGALY; CELL CULTURE; DRUG EFFECTS; HEART MUSCLE CELL; METABOLISM; PATHOLOGY;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; CARDIOMEGALY; CELLS, CULTURED; GLUCAGON-LIKE PEPTIDE 1; HYPOGLYCEMIC AGENTS; MYOCYTES, CARDIAC; PEPTIDES; RATS; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; VENOMS;

EID: 84947760001     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2015.09.179     Document Type: Article

References (39)

1. J.E. Shaw, R.A. Sicree, and P.Z. Zimmet Global estimates of the prevalence of diabetes for 2010 and 2030 Diabetes Res. Clin. Pract. 87 2010 4 14
2. S. Boudina, and E.D. Abel Diabetic cardiomyopathy revisited Circulation 115 2007 3213 3223
3. K. Huynh, B.C. Bernardo, J.R. McMullen, and et al. Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways Pharmacol. Ther. 142 2014 375 415
4. N. Frey, and E.N. Olson Cardiac hypertrophy: the good, the bad, and the ugly Annu. Rev. Physiol. 65 2003 45 79
5. S.P. Barry, and P.A. Townsend What causes a broken heart-molecular insights into heart failure Int. Rev. Cell Mol. Biol. 284 2010 113 179
6. A. Rohini, N. Agrawal, C.N. Koyani, and et al. Molecular targets and regulators of cardiac hypertrophy Pharmacol. Res. 61 2010 269 280
7. J.O. Mudd, and D.A. Kass Tackling heart failure in the twenty-first century Nature 451 2008 919 928
8. J.J. Holst The physiology of glucagon-like peptide 1 Physiol. Rev. 87 2007 1409 1439
9. Y. Wei, and S. Mojsov Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences FEBS Lett. 358 1995 219 224
10. J. Lonborg, N. Vejlstrup, H. Kelbaek, and et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction Eur. Heart J. 33 2012 1491 1499
11. E. Robinson, R.S. Cassidy, M. Tate, and et al. Exendin-4 protects against post-myocardial infarction remodelling via specific actions on inflammation and the extracellular matrix Basic Res. Cardiol. 110 2015 20
12. A.K. Bose, M.M. Mocanu, R.D. Carr, and et al. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury Diabetes 54 2005 146 151
13. M.H. Noyan-Ashraf, M.A. Momen, K. Ban, and et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice Diabetes 58 2009 975 983
14. L.A. Nikolaidis, D. Elahi, T. Hentosz, and et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy Circulation 110 2004 955 961
15. I. Poornima, S.B. Brown, S. Bhashyam, and et al. Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat Circ. Heart Fail. 1 2008 153 160
16. Q. Liu, C. Anderson, A. Broyde, and et al. Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure Cardiovasc. Diabetol. 9 2010 76
17. A.K. Wong, J. Howie, J.R. Petrie, and et al. AMP-activated protein kinase pathway: a potential therapeutic target in cardiometabolic disease Clin. Sci. (Lond.) 116 2009 607 620
18. A.Y. Chan, V.W. Dolinsky, C.L. Soltys, and et al. Resveratrol inhibits cardiac hypertrophy via AMP-activated protein kinase and Akt J. Biol. Chem. 283 2008 24194 24201
19. A.Y. Chan, C.L. Soltys, M.E. Young, and et al. Activation of AMP-activated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte J. Biol. Chem. 279 2004 32771 32779
20. S. Kang, E.R. Chemaly, R.J. Hajjar, and et al. Resistin promotes cardiac hypertrophy via the AMP-activated protein kinase/mammalian target of rapamycin (AMPK/mTOR) and c-Jun N-terminal kinase/insulin receptor substrate 1 (JNK/IRS1) pathways J. Biol. Chem. 286 2011 18465 18473
21. L. Han, Y. Yu, X. Sun, and et al. Exendin-4 directly improves endothelial dysfunction in isolated aortas from obese rats through the cAMP or AMPK-eNOS pathways Diabetes Res. Clin. Pract. 97 2012 453 460
22. M.H. Noyan-Ashraf, E.A. Shikatani, I. Schuiki, and et al. A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity Circulation 127 2013 74 85
23. X.Y. Miao, Z.Y. Gu, P. Liu, and et al. The human glucagon-like peptide-1 analogue liraglutide regulates pancreatic beta-cell proliferation and apoptosis via an AMPK/mTOR/P70S6K signaling pathway Peptides 39 2013 71 79
24. C. Liu, R. Xue, D. Wu, and et al. REDD1 attenuates cardiac hypertrophy via enhancing autophagy Biochem. Biophys. Res. Commun. 454 2014 215 220
25. D.I. Kim, M.J. Park, J.H. Choi, and et al. Hyperglycemia-induced GLP-1R downregulation causes RPE cell apoptosis Int. J. Biochem. Cell Biol. 59 2015 41 51
26. R. Gros, X. You, L.L. Baggio, and et al. Cardiac function in mice lacking the glucagon-like peptide-1 receptor Endocrinology 144 2003 2242 2252
27. G. Xu, H. Kaneto, D.R. Laybutt, and et al. Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes Diabetes 56 2007 1551 1558
28. G. Svegliati-Baroni, S. Saccomanno, C. Rychlicki, and et al. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis Liver Int. 31 2011 1285 1297
29. X. Zhao, G. Liu, H. Shen, and et al. Liraglutide inhibits autophagy and apoptosis induced by high glucose through GLP-1R in renal tubular epithelial cells Int. J. Mol. Med. 35 2015 684 692
30. A. Mima, J. Hiraoka-Yamomoto, Q. Li, and et al. Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCbeta activation in diabetes Diabetes 61 2012 2967 2979
31. B.A. Rose, T. Force, and Y. Wang Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale Physiol. Rev. 90 2010 1507 1546
32. C.P. Liang, S. Han, G. Li, and et al. Impaired MEK signaling and SERCA expression promote ER stress and apoptosis in insulin-resistant macrophages and are reversed by exenatide treatment Diabetes 61 2012 2609 2620
33. S. Bhashyam, A.V. Fields, B. Patterson, and et al. Glucagon-like peptide-1 increases myocardial glucose uptake via p38alpha MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy Circ. Heart Fail. 3 2010 512 521
34. S. Ben-Shlomo, I. Zvibel, M. Shnell, and et al. Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase J. Hepatol. 54 2011 1214 1223
35. S.L. Samson, P. Sathyanarayana, M. Jogi, and et al. Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial Diabetologia 54 2011 3093 3100
36. R. Shibata, N. Ouchi, M. Ito, and et al. Adiponectin-mediated modulation of hypertrophic signals in the heart Nat. Med. 10 2004 1384 1389
37. M. Shimano, N. Ouchi, K. Nakamura, and et al. Cardiac myocyte follistatin-like 1 functions to attenuate hypertrophy following pressure overload Proc. Natl. Acad. Sci. U. S. A. 108 2011 E899 E906
38. S. Sciarretta, M. Volpe, and J. Sadoshima Mammalian target of rapamycin signaling in cardiac physiology and disease Circ. Res. 114 2014 549 564
39. C.H. Lee, K. Inoki, and K.L. Guan mTOR pathway as a target in tissue hypertrophy Annu. Rev. Pharmacol. Toxicol. 47 2007 443 467